trans-Trimethoxyresveratrol (Synonyms: trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene)

目录号: HY-N1408 纯度: 99.35%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) 是 Resveratrol (HY-16561) 的一种具有口服活性的天然衍生物。与 Resveratrol 相比，Trans-Trimethoxyresveratrol 具有更强的抗癌特性，能够更好地抑制癌细胞增殖、诱导细胞周期停滞、减少转移、并诱导细胞凋亡 (apoptosis)。Trans-Trimethoxyresveratrol 可通过 VEGFR2 发挥抗血管作用，导致微管和微管蛋白解聚。Trans-Trimethoxyresveratrol 可用于抗血管新生和癌症 (如非小细胞肺癌和骨肉瘤) 的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

trans-Trimethoxyresveratrol Chemical Structure

CAS No. : 22255-22-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥390	In-stock
50 mg	￥350	In-stock
100 mg	￥600	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

trans-Trimethoxyresveratrol 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 VEGFR 亚型特异性产品:

查看所有亚型

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

查看 Caspase 亚型特异性产品:

查看所有亚型

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

生物活性
纯度 & 产品资料
参考文献

生物活性

Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561). Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through VEGFR2. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma)^[1]^[2]^[3]^[4]^[5]^[6].

IC₅₀ & Target^[2]

Caspase 3

VEGFR2

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
BT-549	IC₅₀	15.6 μM Compound: 3	Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
BXPC-3	GI₅₀	0.35 μg/mL Compound: 1b	Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
Caco-2	IC₅₀	11.95 μM Compound: 9	Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
DU-145	GI₅₀	1.5 μg/mL Compound: 1b	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
HCT-116	IC₅₀	5.7 μM Compound: 8E	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21215623]
HEK293	IC₅₀	28.3 μM Compound: 5H6	Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 18487053]
HeLa	IC₅₀	13.3 μM Compound: 3	Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
HepG2	IC₅₀	> 100 μM Compound: TMS; 66	Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
HT-29	IC₅₀	14 μM Compound: TMS; 66	Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
HT-29	IC₅₀	16.1 μM Compound: 9	Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
IMR-90	IC₅₀	2.1 μM Compound: 8E	Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay	[PMID: 21215623]
K562	IC₅₀	6.39 μM Compound: TMRV	Cytotoxicity against Homo sapiens (human) K562 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0159-y
KB	IC₅₀	10.3 μM Compound: 2	Cytotoxicity against human KB cells after 48 hrs Cytotoxicity against human KB cells after 48 hrs	[PMID: 17000031]
KB	IC₅₀	17.7 μM Compound: 3	Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
LLC-PK1	IC₅₀	20 μM Compound: 3	Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
MCF7	IC₅₀	1.1 μM Compound: 8E	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 21215623]
MCF7	IC₅₀	8.41 μM Compound: TMRV	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0159-y
NCI-H460	GI₅₀	0.62 μg/mL Compound: 1b	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
SF-268	GI₅₀	0.56 μg/mL Compound: 1b	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
SK-BR-3	IC₅₀	111.8 μM Compound: TMS; 66	Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
SK-MEL	IC₅₀	12.2 μM Compound: 3	Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SK-OV-3	IC₅₀	55.5 μM Compound: 3	Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SW480	IC₅₀	54 μM Compound: 3	Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs	[PMID: 20395019]
Vero	IC₅₀	26.7 μM Compound: 3	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]

体外研究
(In Vitro)

Trans-Trimethoxyresveratrol 对多种肿瘤细胞具有显著的细胞毒性，对 A549 细胞的 IC₅₀ 为 0.8 g/mL，对 MDA-MB-231 细胞的 IC₅₀ 为 1.2 μM，对 LNCaP 细胞的 IC₅₀ 为 2.5 μM^[1]。
Trans-Trimethoxyresveratrol (1-100 μM，24-72 h) 在抑制内皮细胞增殖、出芽、胶原凝胶侵袭和形态发生方面的效力是白藜芦醇的 30-100 倍 (ID₅₀ = 0.3-3.0 μM)^[2]。
Trans-Trimethoxyresveratrol (1 μM，3 h) 可显著破坏微管网络并抑制管腔形成^[2]。
Trans-Trimethoxyresveratrol (1 μM，24 h) 仅在亚融合的内皮细胞中诱导凋亡，并在离体大鼠主动脉环测定中诱导未成熟血管的凋亡退化^[2]。
Trans-Trimethoxyresveratrol (0.1 μM，6 h) 能快速 (30 分钟内) 使斑马鱼胚胎中的血流停止，且已形成的血管可在 6 小时内消失^[2]。
Trans-Trimethoxyresveratrol (300 pmol/implant，48 h) 可抑制鸡胚脉管区的血管生长，并导致该区域已存在的血管消失^[2]。
Trans-Trimethoxyresveratrol (3-100 μM，20 h) 可下调 VEGFR2 并诱导斑马鱼胚胎的 G2/M 期细胞周期阻滞^[3]。
Trans-Trimethoxyresveratrol (0.5-50 μM，48 h) 通过上调 miR-345 和 miR-498 抑制 MAPK/Akt/Bcl-2 通路，从而降低 H1299 和 PC-9/GR 细胞对 Gefitinib (HY-50895) 的耐药性^[4]。
Trans-Trimethoxyresveratrol (1-10 μM，0-24 h) 可诱导 ROS 生成和 DNA 损伤，激活 p53/PUMA/Bax 通路，并增强 143B 细胞的凋亡敏感性^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[3]

Cell Line:	zebrafish embryos
Concentration:	10 μM
Incubation Time:	20 h
Result:	Suppressed transcription of VEGFR2.

Cell Cycle Analysis^[3]

Cell Line:	zebrafish embryos
Concentration:	3, 10, 30 and 100 μM
Incubation Time:	20 h
Result:	Induced cell-cycle arrest at G2/M phase.

Western Blot Analysis^[4]

Cell Line:	H1299 and PC-9/GR cells
Concentration:	0.5, 5 and 50 μM
Incubation Time:	48 h
Result:	Decreased the Bcl-2/Bax and p-Akt/Akt while Increased PC-9/GR.

RT-PCR^[4]

Cell Line:	H1299 and PC-9/GR cells
Concentration:	5 μM
Incubation Time:	48 h
Result:	Increased the levels of miR-345 and miR-498. Increased the Bax and caspase-3, and decreased Bcl-2.

Western Blot Analysis^[6]

Cell Line:	143B cells
Concentration:	2.5 μM
Incubation Time:	1, 2, 4, 8, 16 and 24 h
Result:	Activated caspases and increased PARP-1 cleavage. Promoted the phosphorylation of p53, and upregulated PUMA and Bax. Increased the level of γH2AX.

体内研究
(In Vivo)

Trans-Trimethoxyresveratrol (30 mg/kg，口服，每日一次，持续 30 天) 在 H1299 细胞诱导的异种移植小鼠模型中发挥抗肿瘤作用^[4]。
Trans-Trimethoxyresveratrol (1 mg/kg，口服，每两天一次，持续 4 周) 在 143B 细胞诱导的小鼠异种移植模型中显著抑制肿瘤生长^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	H1299 cells induced xenograft model established in BALB/c nude mice^[4]
Dosage:	30 mg/kg alone or with 25 mg/kg Gefitinib (HY-50895)
Administration:	Oral administration (p.o.), once daily for 30 days
Result:	The growth rates of tumour volume and weight were smaller but that the combined inhibition was more remarkable.

Animal Model:	143B cells induced xenograft model established in BALB/c nude mice^[6]
Dosage:	1 mg/kg and 0.1 mg/kg TNF-related apoptosis-inducing ligand (TRAIL)
Administration:	Oral administration (p.o.), every two days for 4 weeks
Result:	Inhibited the development ofosteosarcoma without significant toxicity.

分子量

270.32

Formula

C₁₇H₁₈O₃

CAS 号

22255-22-7

性状

固体

颜色

White to off-white

结构分类

Stilbenes

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 50 mg/mL (184.97 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.6993 mL	18.4966 mL	36.9932 mL
5 mM	0.7399 mL	3.6993 mL	7.3986 mL
10 mM	0.3699 mL	1.8497 mL	3.6993 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.25 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.25 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.25 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.35%

选择批次：

Data Sheet (659 KB) SDS (758 KB)

COA (284 KB) HNMR (143 KB) LCMS (95 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Aldawsari FS, Velázquez-Martínez CA. 3,4',5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency. Invest New Drugs. 2015 Jun;33(3):775-86. [Content Brief]

[2]. Belleri M,et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol. 2005 May;67(5):1451-9. [Content Brief]

[3]. Alex D, et al. Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cell Biochem. 2010 Feb 1;109(2):339-46. [Content Brief]

[4]. Lu M, et al. Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. J Cell Mol Med. 2019 Apr;23(4):2431-2441. [Content Brief]

[5]. Lin HS, Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. J Pharm Sci. 2011 Oct;100(10):4491-500. [Content Brief]

[6]. Feng Y, et al. Resveratrol Derivative, Trans-3, 5, 4'-Trimethoxystilbene Sensitizes Osteosarcoma Cells to Apoptosis via ROS-Induced Caspases Activation. Oxid Med Cell Longev. 2021 Mar 25;2021:8840692. [Content Brief]

trans-Trimethoxyresveratrol 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.6993 mL	18.4966 mL	36.9932 mL	92.4830 mL
	5 mM	0.7399 mL	3.6993 mL	7.3986 mL	18.4966 mL
	10 mM	0.3699 mL	1.8497 mL	3.6993 mL	9.2483 mL
	15 mM	0.2466 mL	1.2331 mL	2.4662 mL	6.1655 mL
	20 mM	0.1850 mL	0.9248 mL	1.8497 mL	4.6241 mL
	25 mM	0.1480 mL	0.7399 mL	1.4797 mL	3.6993 mL
	30 mM	0.1233 mL	0.6166 mL	1.2331 mL	3.0828 mL
	40 mM	0.0925 mL	0.4624 mL	0.9248 mL	2.3121 mL
	50 mM	0.0740 mL	0.3699 mL	0.7399 mL	1.8497 mL
	60 mM	0.0617 mL	0.3083 mL	0.6166 mL	1.5414 mL
	80 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1560 mL
	100 mM	0.0370 mL	0.1850 mL	0.3699 mL	0.9248 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

trans-Trimethoxyresveratrol22255-22-7trans-trismethoxy Resveratrol(E)-Resveratrol trimethyl ether trans-3,5,4'-TrimethoxystilbeneVEGFRReactive Oxygen Species (ROS)CaspaseApoptosisVascular endothelial growth factor receptorResveratrol analoguesAnticancerProstate cancerChemopreventionAntioxidantInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

trans-Trimethoxyresveratrol (Synonyms: trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene)

trans-Trimethoxyresveratrol 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 VEGFR 亚型特异性产品:

查看 Caspase 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

trans-Trimethoxyresveratrol 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

trans-Trimethoxyresveratrol (Synonyms: trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene)

trans-Trimethoxyresveratrol 相关抗体

trans-Trimethoxyresveratrol 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 VEGFR 亚型特异性产品:

查看 Caspase 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

trans-Trimethoxyresveratrol 相关抗体:

摩尔计算器

稀释计算器

trans-Trimethoxyresveratrol 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z